Cargando…

Reclassification of Salivary Gland Aspirates Based on “The Milan System for Reporting Salivary Gland Cytology”: A Five-Year Retrospective Study

INTRODUCTION: The Milan System for reporting salivary gland cytopathology helps standardize reporting systems across institutions, improve communication between clinicians and pathologists and guide the clinical management of patients. AIMS: This study was undertaken to evaluate the utility of the M...

Descripción completa

Detalles Bibliográficos
Autores principales: Pahwa, Saloni, Panjwani, Poonam, Gnanapriya, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585809/
https://www.ncbi.nlm.nih.gov/pubmed/36277807
http://dx.doi.org/10.4103/joc.joc_106_21
Descripción
Sumario:INTRODUCTION: The Milan System for reporting salivary gland cytopathology helps standardize reporting systems across institutions, improve communication between clinicians and pathologists and guide the clinical management of patients. AIMS: This study was undertaken to evaluate the utility of the Milan system classification in cytology reporting. SETTINGS AND DESIGN: The present study is a retrospective study conducted over a period of five years in tertiary care centre. METHODS AND MATERIALS: All the cases of salivary gland aspirates were reviewed and reclassified into six diagnostic categories according to the Milan system of reporting salivary gland cytology (MSRSGC). Cytological diagnosis was correlated with the histopathological diagnosis wherever available. RESULTS: A total of 258 cases were classified using the Milan system as non-diagnostic (20.9%), non-neoplastic (26.3%), atypia of undetermined significance (4.7%), neoplasm benign (37.5%), neoplasm of uncertain malignant potential (3.5%), suspicious for malignancy (0.4%), and malignancy (6.6%). Cytohistological discordance was noted among 8/76 cases (10.5%). The sensitivity and specificity of FNAC were 75% and 98.5%, respectively. The risk of malignancy was 14.2% for Category I, 9% for II, 50% for III, zero for IVA and IVB, and 83.3% for category VI. CONCLUSIONS: The new classification system helps pathologists to standardize reporting leading to better clinical and surgical management.